Plant extracts for the treatment of increased bone resorption.
Patent Information
- Application Number
- MYPI1998001715
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 1997-05-06
- Filing Date
- 1998-04-17
- Publication Date
- 1998-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for osteoporosis and related conditions with increased bone resorption, such as osteoporosis induced by hormone deficiency or aging, are inadequate in effectively inhibiting bone resorption, leading to bone loss and fractures.
The use of extracts or concentrates from plants belonging to the botanical families of Liliaceae, Umbelliferae, and Cruciferae, specifically from Allium, Petroselinum, Brassica, and Eruca, which are processed into nutritional or pharmaceutical compositions to inhibit bone resorption, including onion, parsley, broccoli, and bear's garlic extracts, are used to create formulations that can be administered to treat or prevent conditions characterized by increased bone resorption.
These plant extracts significantly reduce bone resorption, as evidenced by decreased urinary excretion of [3H]-tetracycline in rats and in vitro assays, demonstrating their effectiveness in treating and preventing osteoporosis and other bone-related diseases.
Abstract
Description
PLANT EXTRACTS FOR THE TREATMENT OF INCREASED BONERESORPTIONThe present invention relates to nutritional or pharmaceutical compositions comprisingextracts or concentrates of certain plants and their use as inhibitors of bone resorption.The most common metabolic bone disorder is osteoporosis. Osteoporosis can begenerally defined as the reduction in the quantity of bone, either from the reduction inbone formation or the acceleration of bone resorption, in either event the result is adecrease in the amount of skeletal tissue. Osteoclasts (bone resorbing cells) areresponsible for the excavation of a portion of bone during the resorption process. Afterresorption, osteoblasts (bone forming cells) appear, which then refill the resorbedportion with new bone.In young healthy adults, the rate at which the osteoclasts and osteoblasts are formedand operate maintains a balance between bone resorption and bone formation.However, as normal consequence of aging, an imbalance in this remodeling processdevelops, resulting in loss of bone. As imbalance continues overtime, the reduction inbone mass and thus bone strength leads to fractures.Many compositions and methods are described in the medical literature for thetreatment of osteoporosis. For example, estrogens, calcitonin and bisphosphonates areknown to be effective inhibitors of bone resorption.It has now surprisingly been found that products derived from certain plants orvegetables which belong for example to the botanical families of liliaceae, umbelliferaeand cruciferae have a potent inhibitory effect on bone resorption.Osteoporosis as used herein includes osteoporosis induced by hormone deficiency (e.g.postmenopausal) and old age, as well as secondary osteoporosis such as osteoporosissecondary to steroid treatment or secondary to malnutrition caused by anorexianervosa.The present invention also foresees the use of an extract or concentrate from a plantselected from the group consisting of allium, petroselinum, brassica and eruca extractsand concentrates in the preparation of a medicament or nutritional formulation for thetreatment or prophylaxis of a disease or condition which is characterized by increasedbone resorption, such as Paget's disease, tumor-induced bone disease or particularlyosteoporosis.The the extracts and concentrates from allium, petroselinum, brassica and / or eruca arevegetable extracts or concentrates according to the invention..As used herein, the term vegetable refers to a herbaceous plant which has an edibleportion which is consumed by humans in either raw or cooked form. The edible portionmay be a root, a tuber or storage stem, the stem, a bud, a bulb, such as onion andgarlic; a petiole or leafstalk, a leaf, such as cabbage, and parsley an immature flower,such as cauliflower and broccoli a seed; the immature fruit or mature fruit.As used herein, the term allium refers to the genus allium (latin for garlic, a member ofthe onion family) and includes for example any member of the botanical species Alliumcepa (onion), Allium ascalonicum (shallot), Allium ampeloprasum (leek / great-headed-garlic), Allium porrum (leek), Allium schoenoprasum (chive), Allium ursinum (bear'sgarlic), Allium sativum (garlic) or Allium fistulosum (bunching onion). Preferred speciesare Allium ascalonicum (shallot), Allium porrum (leek), Allium cepa (onion) and Alliumursinum (bear's garlic, also known as bear paw garlic), particularly the latter two,whereby Allium cepa is particularly preferred. Examples of members of the speciesAllium cepa are common onions (with red or white or yellow skins) or shallots, wherebyred or white common onions are preferred.The onion extracts and concentrates are prepared e.g. from the whole eatable part ofthe vegetable. Suitable chive extracts and concentrates are obtained e.g. from chiveherbs. Suitable bear's garlic extracts and concentrates are obtained e.g. from bear'sgarlic bulbs, fresh herbs or from the whole blooming plant, preferably they are obtainedform fresh herbs.The term petroselinum as used herein refers to the genus petroselinum (common nameparsley) and includes for example any member of the botanical species Petroselinumcrispum. Examples are Petroselinum crispum crispum, that is common parsley withcurly leaves, Petroselinum crispum radiosum or Petroselinum crispum var.neapolitanum also known as Italian Parsley with flat leaves.Suitable petroselinum extracts or concentrates may be produced e.g. from roots, fruitsor seeds, or particularly from herbs.As used herein the term brassica refers to the genus brassica (latin for cabbage) andincludes for example any member of the botanical species Brassica oleracea, Brassicanapus, Brassica rapa, Brassica alboglabra, Brassica juncea, Brassica perviridis,Brassica alba and Brassica nigra.Brassica oleracea is a preferred species, particularly preferred members of this speciesare Brassica oleracea var. italica, i.e. broccoli, or Brassica oleracea var. gemmifera, i.e.Brussels sprouts. Broccoli extracts and concentrates are particularly preferred asbrassica extract or concentrate. Suitable extracts and concentrates of brassicaoleraceae species are produced advantageously from the whole eatable part of thevegetable or from the freshly germinated sprouts or shoots.As used herein the term eruca refers to the genus eruca and includes in particular anymember of the botanical species Eruca sativa (wild form) or Eruca vesicaria subsp.sativa (cultivated form) for which the common name is arrugula or roquette.The plant / vegetable extracts and concentrates of the invention are preferably obtainedfrom an edible portion of the plant or vegetable. By edible portion is meant the portionwhich is consumed by humans in either raw or cooked form.A preferred group of inventive plant / vegetable extracts and concentrates comprisesconcentrates or extracts from any member of the botanical species Allium cepa, Alliumascalonicum, Allium ursinum, Petroselinum crispum, Brassica oleracea or Eruca sativa.A more preferred group of inventive plant / vegetable extracts and concentratescomprises extracts and concentrates from any member of the botanical species Alliumcepa, Petroselinum crispum (in particular Petroselinum crispum crispum andPetroselinum crispum var. neapolitanum) and Brassica oleracea (in particular Brassicaoleracea var. italica), particularly extracts and concentrates of onions (Allium cepa),Italian Parsley (Petroselinum crispum var. neapolitanium) or broccoli (Brassica oleraceavar. italica). The use of onion extracts (in particular white onion extracts) is particularlypreferred.The extracts and concentrates of the above-mentioned plants or vegetables may be inliquid form or in solid form such as in granulate or powder form.Suitable plant or vegetable concentrates are obtainable e.g. by drying or freeze-dryingthe fresh-cut plants or vegetables or the respective roots, fruits or seeds thereof andthen optionally grinding or granulating the dried material; or by squeezing the fresh-cutplants or vegetables or the respective roots, fruits or seeds thereof and gathering theliquid fraction and optionally drying it. The use of a concentrate of the above-mentionedplants or vegetables in solid form and particularly in powder form is preferred.Suitable methods of obtaining extracts of the above-mentioned plants or vegetables areknown in the art. The plant or vegetable extracts are obtainable e.g. by extracting thefresh-cut or dried plants or vegetables or the respective roots, fruits or seeds thereof forexample with water or with one or more food grade solvents or with a mixture of waterand one or more food grade solvents. Suitable food grade solvents include propane,butane, butyl acetate, ethyl acetate, ethanol, carbon dioxide, acetone, nitrous oxide,methanol and propan-2-ol, whereby ethanol and carbon dioxide are preferred; ethanolis a particularly preferred food grade solvent. After the extraction step the liquid phaseis optionally concentrated or dried by evaporation or freeze drying. The fresh-cut ordried plant or vegetable material may be introduced in cold or preferably hot waterand / or solvent, preferably water or a mixture of water with one or more solvents, for aspecified period of time, which may vary within wide ranges depending on the kind ofplant or vegetable material or solvent used but commonly amounts for example to 1 to30 minutes, preferably 2 to 15 minutes and most preferred 5 to 10 minutes for a waterextraction and for example 30 to 90 minutes, preferably 60 minutes for an ethanol / waterextraction. For a water extraction the temperature preferably lies in the range of 85 to95°C and for an alcohol / water extraction the temperature preferably lies in the range of55 to 65°C. For a carbon dioxide extraction, the extraction preferably takes place at 0to 40°C and at super-critical pressure (e.g. 80 x 105 - 200 x 105 Pa (80-200 bar)). Afterthe extraction the liquid phase is separated and advantageously concentrated orevaporated to dryness according to known methods. To obtain a concentrated extracttwo or more extraction steps as described above may be combined. Moreover, the plantor vegetable extracts may be obtained by introducing the fresh-cut or dried plant orvegetable in water and subjecting the mixture to a steam distillation. The distillate iscollected and is then advantageously concentrated or evaporated to dryness.The extract may be used in liquid form, particularly in aqueous form, or in solid form,particularly in granulate or powder form. If the extract is in liquid form, it has a solidcontents of for example from 1 to 25 % by weight, preferably from 2 to 20 % by weightand most preferred from 2 to 15 % by weight.The amount of inventive plant / vegetable extract or concentrate to be supplied may varywithin wide ranges, depending on i.a. the desired treatment, subject to be treated andhis needs. Thus, where the subject to be treated is an adult person (typically of ca. 60to 75 kg body weight), a satisfactory inhibitory effect on bone resorption is, in generalobtained with compositions formulated to allow a daily administration of 0.1 to 20 grams,preferably 0.2 to 15 grams and most preferred 0.4 to 10 grams of allium, petroselinum,brassica and / or eruca concentrate or extract (on a solvent-free basis).Suitable nutritional compositions comprising the above-mentioned plant / vegetableextracts or concentrates represent a further object of the invention. They arecharacterized in that they comprise(a) at least one plant / vegetable extract or concentrate selected from the groupconsisting of allium, petroselinum, brassica and eruca extracts and concentrates,(b) a calcium source, and(c) at least one energy source selected from the group consisting of carbohydrate,fat and nitrogen sources, and optionally(d) Vitamin D.Regarding component (a), the definitions, preferences and amounts given before for theallium, petroselinum, brassica and eruca extracts and concentrates apply. It is alsopossible to have a mixture of two or more of said plant / vegetable extracts andconcentrates as component (a). The nutritional compositions of the inventionconveniently comprise (in % by weight) for example from approximately 0.1 to 40 %,preferably from approximately 3 to 25 % and most preferred from 5 to 15 % ofplant / vegetable extract or concentrate component (a).The calcium source (b) may comprise any physiological acceptable inorganic or organiccompound containing calcium. Examples are inorganic calcium salts, for examplecalcium chloride, calcium phosphate, calcium sulfate, calcium oxide, calcium hydroxideor calcium carbonate, or organic calcium components like whole or skim milk powder,calcium caseinate or calcium salts of organic acids such as calcium citrate, calciummaleate, or mixtures thereof. The use of organic calcium compounds, particularly skimmilk powder, calcium caseinate or mixtures thereof, as calcium source (b) is preferred.The amount of calcium component to be supplied may vary within wide ranges. Ingeneral, the inventive compositions comprise in one unit dosage from about 100 mg to1000 mg, preferably 200 mg to 700 mg and most preferred 300 to 600 mg of calcium(on an elemental basis).The nutritional compositions of the invention conveniently comprise (in % by weight) forexample from approximately 1 to 60 %, preferably from approximately 5 to 50 % andmost preferred from 10 to 40 % of calcium component (b).Suitable carbohydrate sources include for example maltodextrins, starch, lactose,glucose, sucrose, fructose, xylit and / or sorbit. In these forms the carbohydrates are bothenergy suppliers and sweeteners. The inventive compositions may contain one or moredifferent carbohydrate sources.Suitable fat sources include omega-6 polyunsaturated fatty acid sources, omega-3polyunsaturated fatty acid sources, mono-unsaturated fatty acid sources, medium chainfatty acid sources (i.e. C6-C12-fatty acids); or mixtures thereof. The above-mentionedfatty acids may be employed in each case in form of the free acid, in mono-, di- orparticularly in triglyceride form, or in form of a pharmacological or nutritional acceptablenatural source.Suitable natural sources of omega-6 polyunsaturated fatty acids include vegetable oilssuch as safflower oil, sunflower oil, soya oil, cotton oil and corn oil. Suitable naturalsources of omega-3 polyunsaturated fatty acids include linseed oil and fish oils such asmenhaden oil, salmon oil, mackerel oil, tuna oil codliver oil and anchovy oil.Suitable natural sources of mono-unsaturated fatty acid sources are particularly omega-9 mono-unsaturated fatty acids, for example olives, canola, safflower (hybrids) andsunflower (hybrids).A preferred fat source comprises triglyceride oils supplying the desired amounts ofomega-6 polyunsaturated fatty acids and omega-3 polyunsaturated fatty acids andwhich are rich in the medium chain fatty acid residues (i.e. residues of C6-C12 fatty acid)and / or mono-unsaturated fatty acid residues. The inventive compositions may containone or more different fat sources.Examples of suitable nitrogen sources of the inventive nutritional compositions includesources containing nutritionally acceptable proteins such as soy bean derived proteins;milk proteins such as whey proteins or caseinates; and / or protein hydrolysates; and / oressential amino acids mixtures in free amino acid form or salt form; and / or compoundsassociated with the synthesis of polyamines, such as arginine, arginine precursors,ornithine and the like, in free amino acid form or salt form.Preferred nitrogen sources of the nutritional compositions are(i) soy bean derived proteins, which may be employed in the form of soy beans orin the form of any suitable soja extract or concentrate, for example in form of soyflour, dried soy sprouts, soybean milk, or as dried aqueous extract from soybeans;or(ii) milk proteins, for example whey derived proteins or caseinates which may beemployed for example in the form of whey powder, caseinate salts such ascalcium caseinate and / or whole or preferably skim milk powder and / or(iii) a mixture of essential amino acids and / or(iv arginine as nitrogen source.Milk proteins such as whey powder, caseinates, particularly calcium caseinate, and / orskim milk powder are another particularly preferred nitrogen source of the claimednutritional compositions. The inventive compositions may contain one or more differentnitrogen sources.The nutritional compositions comprise (in % by weight) for example, from approximately0.1 % to 98,9 %, preferably from approximately 1 to approximately 95 %, and mostpreferred from 10 to 90 % of energy source component (c).The contribution of the nitrogen source, carbohydrate source and fat source to thecaloric of the inventive nutritional compositions may vary within wide ranges. Forexample, the carbohydrate source provides for 30 to 70 % of the total energy supply,the nitrogen source for 5 to 45% and the fat source for 0. 1 to 15 % of the total energysupply of the composition. In preferred compositions of the invention the carbohydratesource provides for 40 to 60 % of the total energy supply, the nitrogen for 20 to 35 %and the fat source for 3 to 12 % of the total energy supply of the composition.A preferred energy source (c) of the inventive compositions comprises30 to 70 % of the total energy supply of one or more carbohydrate sources selectedfrom the group consisting of maltodextrins, starch, lactose, glucose, sucrose, fructose,xylit and sorbit;5 to 45 % of the total energy supply of one or more nitrogen sources selected from thegroup consisting of soy bean derived proteins, milk proteins, a mixture of essentialamino acids and arginine and0. 1 to 15 % of the total energy supply of one or more fat sources comprising omega-S-and omega-6-polyunsaturated fatty acids.A particularly preferred energy source (c) of the inventive compositions comprises40 to 60 % of the total energy supply of one or more carbohydrate sources selectedfrom the group consisting of maltodextrins, starch, lactose, glucose, sucrose, fructose,xylit and sorbit;20 to 35 % of the total energy supply of one or more nitrogen sources selected from thegroup consisting of soy bean derived proteins, skim milk powder and caseinates; and3 to 12 % of the total energy supply of one or more fat sources comprising omega-S-and omega-6-polyunsaturated fatty acids.The amount of Vitamin D (optional component (d)) to be supplied may vary within wideranges. In general, the inventive compositions comprise in one unit dosage from about400 IU to 1000 IU, preferably about 500 IU.The nutritional formulations of the invention may comprise other nutritionally acceptablecomponents such as vitamins, minerals, trace elements, fibers (preferably solublefibers), flavors, preservatives, colorants, sweeteners, emulsifiers and the like.Examples of vitamins suitable for the incorporation in the composition of the inventioninclude Vitamin A, Vitamin D, Vitamin E, Vitamin K, Vitamin C, folic acid, thiamin,riboflavin, Vitamin B6, Vitamin B12, niacin, biotin and panthotenic acid in pharmaceuticalor nutritionally acceptable form.Examples of mineral elements and trace elements suitable for the incorporation in thecomposition of the invention include sodium, potassium, phosphorous, magnesium,copper, zinc, iron, selenium, chromium and molybdenum in pharmaceutical ornutritionally acceptable form.The term soluble fiber as used herein refers to fibers which are able to substantiallyundergo fermentation in the colon to produce short chain fatty acids. Examples ofsuitable soluble fibers include agar-agar, alginates, carubin, carrageenan, gum arabic,guar gum, karayagum, locust bean gum, pectin, tragacanth, orxanthangum. They maybe hydrolysed or not.Suitable flavors include natural or artificial flavors, for example fruit flavors such asbanana, orange, peach, pineapple or rasberry; vegetable flavors; or vanilla, cocoa,chocolate, coffee and the like.Preferred ingredients of the inventive nutritious compositions in addition to components(a), (b), (c) and (d) comprise beta-carotene (Vitamin A), Vitamin E, Vitamin C, thiamin,Vitamin B,, B6 and / or B12, potassium, magnesium, selenium, zinc, phosphorous andsoluble fiber in pharmaceutical or nutritionally acceptable form.The nutritional compositions may comprise (in % by weight) for example, fromapproximately 0.1 % to 15 %, preferably from approximately 0.2 to approximately 10%,and most preferred from 0.5 to 5 % of these additional components other thancomponents (a), (b), (c) and optionally (d).The inventive nutritional formulations may be formulated and administered in any formsuitable for enteral administration, for example oral administration or tube feeding, e.g.nasal administration. The formulations are conveniently administered in the form of anaqueous liquid. The formulations suitable for enteral application are accordinglypreferably in aqueous form or in powder or granulate form, whereby the powder orgranulate is conveniently added to water prior to use. For use as tube feeding, theamount of water to be added will i.a. depend on the patient's fluid requirements andcondition.The inventive nutritional compositions may be in form of a complete formula diet (inliquid or powder form), such that, when used as sole nutrition source essentially all dailycaloric, nitrogen, fatty acids, vitamin, mineral and trace element requirements are met.In general, the daily amount to be supplied to adult persons will lie in the range of 750to 3500 kcal / day, in particular of 1000 to 2000 kcal / day. However, the inventivenutritional compositions are preferably intended for use as a dietary supplement. Theamount of energy supplied by a supplement should not be too excessive, in order notto unnecessarily suppress the patients appetite. The supplement convenientlycomprises energy sources in an amount supplying from 50 to 1500 kcal / day, preferably100 to 900 kcal / day and most preferred 150 to 700 kcal / day.The nutritional compositions of the invention which are in liquid form, for example indrink form, or preferably in solid form, for example in granulate or powder form, may beobtained in a manner known per se, e.g. by admixing the ingredients and optionallyadding water.The invention further relates to pharmaceutical compositions in single dose unit formcomprising(a) at least one plant / vegetable extract or concentrate selected from the groupconsisting of allium, petroselinum, brassica and eruca extracts and concentrates,and(b) a pharmaceutical acceptable carrier.These pharmaceutical compositions are compositions for enteral administration, suchas oral, nasal or rectal administration. Suitable pharmaceutical compositions may be inliquid form or preferably in solid form and comprise (in % by weight) for example, fromapproximately 0.001 % to 100 %, preferably from approximately 0.1 to approximately50 %, active ingredient (a).Pharmaceutical compositions for enteral administration are, for example, those in singledose unit forms, such as dragees, tablets, capsules or sachets. They are prepared ina manner known per se, for example by means of conventional mixing, granulating,confectioning, dissolving or lyophilising processes.For example, pharmaceutical compositions for oral administration can be obtained bycombining the active ingredient with solid carriers, optionally granulating a resultingmixture and processing the mixture or granules, if desired or necessary after theaddition of suitable excipients, to form tablets or dragee cores.Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose,mannitol or sorbitol, cellulose preparations and / or calcium phosphates, for example tri-calcium phosphate or calcium hydrogen phosphate, and also binders, such as starchpastes using, for example, corn, wheat, rice or potato starch, gelatin, tragacanth,methylcellulose and / or polyvinylpyrrolidone, and, if desired, disintegrators, such as theabove-mentioned starches, and also carboxymethyl starch, cross-linked polyvinyl-pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate. Excipientsare especially flow-conditioners and lubricants, for example silicic acid, talc, stearic acidor salts thereof, such as magnesium or calcium stearate, and / or polyethylene glycol.Dragee cores are provided with suitable, optionally enteric, coatings, there being usedinter alia concentrated sugar solutions which may contain gum arabic, talc,polyvinylpyrrolidone, polyethylene glycol and / or titanium dioxide, or coating solutions insuitable organic solvents or solvent mixtures or, for the preparation of enteric coatings,solutions of suitable cellulose preparations, such as acetylcellulose phthalate orhydroxypropylmethylcellulose phthalate. Dyes or pigments may be added to the tabletsor dragee coatings, for example for identification purposes or to indicate different dosesof active ingredient.Other orally administrable pharmaceutical compositions are hard gelatin capsules andalso soft, sealed capsules consisting of gelatin and a plasticiser, such as glycerol orsorbitol. The hard gelatin capsules may comprise the active ingredient in the form ofgranules, for example in admixture with fillers, such as lactose, binders, such asstarches, and / or glidants, such as talc or magnesium stearate, and, if desired,stabilisers. In soft capsules the active ingredient is preferably dissolved or suspendedin suitable liquids, such as fatty oils, paraffin oil or liquid polyethylene glycols, it islikewise being possible to add stabilisers.Suitable rectally administrable pharmaceutical compositions are, for example,suppositories that consist of a combination of the active ingredient with a suppositorybase material. Suitable suppository base materials are, for example, natural or synthetictriglycerides, paraffin hydrocarbons, polyethylen glycols or higher alkanols. It is alsopossible to use gelatin rectal capsules which comprise a combination of the activeingredient with a base material. Suitable base materials are, for example, liquidtriglycerides, polyethylenglycols or paraffin hydrocarbons.The inhibitory effect on bone resorption of the inventive plant or vegetable extracts andconcentrates may be assessed by measuring the urinary excretion of [3H]-tetracyclinefrom chronically prelabled rats as described in R.C. Muhlbauer and H. Fleisch, Am JPhysiol 258, R 679-R689 (1990). The method is based on the characteristics (i) that 3H-labeled tetracycline is deposited in hard tissues during their formation; and (ii) whenbone is resorbed, [3H]-tetracycline is released, circulates in blood, and is excreted intothe urine where it can be assessed by counting 3H. This is probably due to the fact that[3H]-tetracycline from bone circulates in a form that binds poorly to hydroxyapatite and,therefore, [3H]-tetracycline once liberated from bone, is only poorly reutilized duringbone turnover, and because of an efficient renal excretion. The method may beperformed as follows: rats are injected subcutaneously twice a week with increasingvolumes of a solution containing [3H]-tetracycline starting shortly after birth until the ageof about six weeks. At the age of about 50 days, the animals are transferred toindividual metabolic cages and every rat is fed with the same amount of a standardizeddiet for about the three weeks. After that, one group of rats is fed with a purified diet,and another group is fed with the purified diet containing in addition a certain amountof an inventive plant or vegetable concentrate or extract. During the experiments, theanimals have free access to demineralized water.When the rats are about 60 days old, daily 24-hour urine collections are started, and the3H contents in urine are determined by liquid scintillation counting. A diagram is thenprepared wherein the [3H]-tetracycline contents in urine of the two groups of rats areplotted as a function of time (days).Suitable experiments show that the plant or vegetable extracts and concentrates of theinvention are capable of considerably decreasing the cumulative [3H]-tetracyclineexcretion in urine of intact males and castrated female rats which indicates a highinhibitory effect on bone resorption. Accordingly, the claimed nutritional andpharmaceutical compositions are useful for the treatment and prophylaxis of all kindsof diseases or conditions which are characterized by increased bone resorption, suchas Paget's disease, tumor-induced bone disease or particularly osteoporosis.The inhibitory effect of the plant or vegetable extracts or concentrates on boneresorption may also be assessed by an in vitro assay (described in Example 3) in whichivory slices, onto which freshly isolated osteoclasts have been settled, are incubatedwith a medium containing the extract or concentrate to be tested. The inhibitory effecton osteoclasts is assessed by counting the osteoclast resorption pits on the ivory slice.In the following Examples, which illustrate the invention, % are parts by weight unlessstated otherwise, and temperatures are given in °C.Example 1:The following is an example of a suitable composition of an inventive Supplement inpowder form.Energy value 229 kcal1) a) Extract 1 obtained by extracting 48.3 g dry broccoli for 10 minutes at 89 + 3°Cwith 483 ml distilled water and then evaporating the extract to dryness.b) Extract 2 obtained by extracting 48.3 g dry Italian Parsley for 10 minutes at 89+ 3°C with 483 ml distilled water and then evaporating the extract to dryness.c) Extract 3 obtained by extracting 26.4 g dry onions for 10 minutes at 89 + 3°Cwith 264 ml distilled water and then evaporating the extract to dryness .d) Extract 4 obtained by extracting 58.9 g dry onions for 10 minutes at 89 + 3°Cwith 589 ml distilled water and then evaporating the extract to dryness, followedby a second extraction of the dried water extract with 324 ml of 85% ethanol / 15%water for one hour at 60°C, cooling to room temperature and keeping over nightat -20°C, decanting the supernatant, evaporating the alcohol and freeze-dryingthe extract.e) Extract 5 obtained by extracting 45.3 g dry onions for one hour at 60°C with453 ml of 85% ethanol / 15% water, filtrating, evaporating the alcohol and freeze-drying the extract.f) Concentrate 6 obtained by drying fresh bear's garlic and grinding it to a finepowder.The above supplement may be mixed with water and taken in appropriate concentrationbetween meals.Example 2: - Effect of H20 extracts of broccoli, dog-parsley and onion on boneresorptionThe effect of the inventive plant or vegetable extracts and concentrates on boneresorption is based on a method as described in R.C. Muhlbauer and H. Fleisch, Am JPhysiol 259, R 679-R689 (1990). Bone resorption is monitored by the urinary excretionof 3H in Wistar rats prelabled from birth for 6 weeks with [3H]-tetracycline as describedin the above-mentioned reference. The rats are then housed in individual metaboliccages and are fed for 10 days with a standard laboratory chow (Kliba 331,Klingentalmuhle, Kaiseraugst, Switzerland) containing 1.0 g Ca, 0.7 g P, and 80 IU ofvitamin D3 / 100 g of food. After this adaptation period, all rats received a diet containing1.0 g Ca, 1.2 g P, and 80 IU of vitamin D3 / 100 g dry weight. This was achieved byadding appropriate amounts of Ca-gluconate and neutral phosphate salts to a basic lowcalcium, low phosphate diet (Sodi 2134, Klingenthalmuhle, Kaiseraugst, Switzerland)in powder form for another 10 days during which urine is collected. Then rats were "pair-fed" receiving 28g of wet food per day. One group (n=6) is switched to a purified diet("Diet P", Sodi 2160, Klingenthalmuhle, Kaiseraugst, Switzerland given as wet food witha water content of 45 + 2% containing 1.0 g Ca, 1.2 g P, and 80 IU of vitamin D3 / 1 OOgdry weight), a second group (n=5) is fed with the purified diet containing in addition 300mg extract from broccoli per day (corresponding to 1.0 gram of dry broccoli extractedfor 10 minutes at 89 ± 3°C with 10 ml distilled water), a third group (n=5) is fed with thepurified diet containing in addition 300 mg extract from Italian Parsley per day(corresponding to 1.0 gram of dry Italian Parsley extracted for 10 minutes at 89 + 3°Cwith 10 ml distilled water), and a fourth group (n=5) is fed with the purified dietcontaining in addition 550 mg extract from onion per day (corresponding to 1.0 gram ofdry onion extracted for 10 minutes at 89 + 3°C with 10 ml distilled water).After 10 days adaptation without urine collection and a further 10 days with urinecollection, the rats are allocated to the different treatment groups. Using the baseline24 hour [3H]-tetracycline excretion as selection criterion, special care is taken to obtainsimilar mean initial values for each group. Thereafter, the rats are switched to thepurified diet with or without inventive extract and daily 24-hour urine collections areperformed over a period of 14 days, and the cumulative [3H]-tetracycline excretion inurine is determined by liquid scintillation counting.After 14 days of treatment the cumulative bone resorption was 9.2%, 9.5% and 17.5%(p<0.05) lower as compared to the control group, in rats daily fed the extracts ofbroccoli, Italian Parsley and onion respectively.Example 3: - Effect of a bear's garlic concentrate on bone resorptionThe same method as described in Example 2 is used except that treatment lasts onlysix days and the test group (n=5) is fed with the purified diet containing in addition 1 gof a concentrate from bear's garlic (obtained by drying and grinding fresh bear's garlic).It was found that bear's garlic inhibits bone resorption in male rats by 13.5% (p<0.05).Example 4: - Effect of onion extract on in vitro resorptionThe effect of an onion extract on in vitro resorption is investigated on osteoclast-mediated resorption (as described in Arnett TR, Spowage M, 1996, Modulation of theresorptive activity of rat osteclasts by small changes in extracellular pH near thephysiological range. Bone 18:277-279) with the following modifications: instead of usingbone wafers, ivory slices are used as mineral substrate to assess osteoclast resorptionpits which are counted under tangential illumination after gold spottering (Vitte C,Fleisch H, Guenther HL, 1996, Bisphosphonates induce osteoblasts to secrete aninhibitor of osteoclast-mediated resorption, Endocrinology 137:2324-2333). In this assayone 4x4 millimeter ivory slice, onto which freshly isolated osteoclasts have been settledis incubated per well of a 48-well plate in 250 pi of a medium containing the extract tobe tested during 24 hours at 37°C in a 5% C02 / air atmosphere. For each dose 8 slicesare used. Osteoclasts are harvested from femurs of newborn rats which are, afterremoving the cartilagenous ends, split in half and chopped transversally. This procedureleads to a cell suspension rich in other cells such as osteoblasts. This permits to testeffects in broad conditions, that is, as to both, direct effect on osteoclast and indirecteffect on the osteoclast mediated by other cells such as osteoblasts.The onion extract is obtained by extracting a fine powder of onion for 10 minutes indistilled water (1 OOg / l) at 90°C, filtrating and freeze-drying the filtrate, followed by asecond extraction of the dry water extract for one hour at 60°C in 85% ethanol / 15%water, cooling to room temperature, keeping over night at -20°C to allow precipitationof unwanted material, decanting the supernatant, evaporating the alcohol and freeze-drying the thus obtained residue, whereby 250 mg freeze-dried onion extract areobtained for each g of dry whole onion.The onion extract (0.017, 0.17, 1.7 mg onion extract / ml medium) inhibited osteoclast-mediated resorption of dentine in a dose-dependent manner, while the number oftartrate-resistant alcaline phosphatase positive (TRAP+) multinucleated cells (MNC) didnot decrease significantly. Thus, the ratio pits / TRAP+ MNC decreased significantly(p<0.001). From this it is concluded that the presence of large numbers of TRAP+ MNCin these cultures despite the additions of onion extract indicate that onion extract is nottoxic to these cells but rather inhibits the activity of osteoclasts.
Claims
CLAIMS 1. Use of a plant extract or concentrate selected from the group consisting of allium, petroselinum, brassica and eruca extracts and concentrates or mixtures thereof in the 5 preparation of a medicament or nutritional formulation for the treatment or prophylaxis of a disease or condition which is characterized by increased bone resorption, such as Paget's disease, tumor-induced bone disease or particularly osteoporosis.
2. The use according to claim 1, wherein an allium, petroselinum, brassica and / or 10 eruca extract or concentrate in solid form is employed.
3. The use according to claim 1 or 2, wherein the medicament or nutritional formulation is formulated to allow a daily administration of 0.1 to 20 grams of allium, petroselinum, brassica and / or eruca extract or concentrate, each on a solvent-free 15 basis.
4. A nutritional composition comprising (a) at least one plant extract or concentrate selected from the group consisting of allium, petroselinum, brassica and eruca extracts and concentrates, 20 (b) a calcium source, and (c) at least one energy source selected from the group consisting of carbohydrate, fat and nitrogen sources, and optionally (d) Vitamin D.
5. A nutritional composition according to claim 4, wherein the plant extract or concentrate is selected from the group consisting of extracts and concentrates of the botanical species Allium cepa, Allium ascalonicum, Allium ursinum, Petroselinum crispum, Brassica oleracea and Eruca sativa. PI 98001715 -216. A nutritional composition according to claim 4 or 5, wherein the plant extract or concentrate is selected from the group consisting of extracts and concentrates from the botanical species Allium cepa, Petroselinum crispum (in particular Petroselinum crispum crispum and Petroselinum crispum var. neapolitanum, and Brassica oleracea (in 5 particular Brassica oleracea var. italica).
7. A nutritional composition according to claims 4 to 6, wherein the plant extract or concentrate is selected from the group consisting of onion, Italian Parsley (Petroselium crispum var, neapolitanum) and broccoli (Brassica oleracea van, italica)extracts and 10 concentrates.
8. A nutritional composition according to claims 4 to 7, wherein the calcium source (b) is an organic calcium salt.
159. A nutritional composition according to claims 4 to 8, wherein the carbohydrate source in component (c) is selected from the group consisting of maltodextrins, starch, lactose, glucose, sucrose, fructose, xylit and sorbit.
10. A nutritional composition according to claims 4 to 9, wherein the fat source in 20 component (c) is selected from the group consisting of omega-6 polyunsaturated fatty acid sources, omega-3 polyunsaturated fatty acid sources, mono-unsaturated fatty acid sources, C6-C12- fatty acid sources, and mixtures thereof.
11. A nutritional composition according to claims 4 to 10, wherein the nitrogen source 25 in component (c) is one or more selected from the group consisting of soy bean derived proteins; milk proteins, protein hydrolysates, a mixture of essential amino acids and arginine.
12. A nutritional composition according to any of claims 4 to 11, wherein the 30 carbohydrate source provides for 30 to 70 % of the total energy supply, the nitrogen PI 98001715 -22source for 5 to 40 % and the fat source for 0.1 to15 % of the total energy supply of the composition.
13. A nutritional composition according to any of claims 4 to 12, which comprises (in 5 % by weight) from 3 to 25 % of component (a), from 5 to 50 % of component (b) and from 1 to 95 % of component (c).
14. A nutritional composition according to any of claims 4 to 13, which comprises in addition (in % by weight) 0.2 to 10 % of other nutritionally acceptable components 10 selected from the group consisting of vitamins, minerals, trace elements, fibers, flavors, preservatives, colorants, sweeteners and emulsifiers.
15. A nutritional composition according to any of claims 4 to 14, which is in the form of a dietary supplement having from 50 to 1500 kcal / day.
16. A nutritional composition according to any of claims 4 to 15, which is in liquid form.
17. A nutritional composition according to any of claims 4 to 15, which is in solid form, particularly in granulate or powder form.
18. A pharmaceutical composition in single dose unit form, comprising (a) two or more plant extract or concentrate selected from the group consisting of allium, petroselinum, brassica and eruca extracts and concentrates, and (b) a pharmaceutical acceptable carrier.
19. A pharmaceutical composition according to claim 18 for enteral administration which is in the form of a dragee, tablet, capsule, sachet or suppository.
